Published: October 02, 2026
For decades, drug development and toxicology have relied on a biological proxy: animal testing. However, from a systems-engineering perspective, animal models are noisy, low-throughput, and highly inconsistent platforms for replicating human physiology. Over 90% of pharmaceutical compounds that demonstrate safety and efficacy in animal trials fail when deployed in human clinical studies. This massive failure rate points to a fundamental system mismatch.
Enter organ-on-a-chip (OOC) technology—a field that merges microfluidic design, micro-electro-mechanical systems (MEMS), and cell biology to create living, bio-hybrid hardware. These devices are essentially physical integrated circuits, but instead of routing electrons through silicon, they route fluids, nutrients, and living cells through precisely etched polymer channels.
